Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scient (MLSS) delivers innovative computer-controlled anesthetic systems designed to improve patient comfort in dental and medical procedures. This dedicated news hub provides real-time updates on the company’s technological advancements, regulatory milestones, and strategic partnerships.
Access authoritative information on MLSS’s global expansion across 25+ countries, product innovations like the CompuDent and CompuMed systems, and financial performance. The curated content serves investors and healthcare professionals seeking to monitor the company’s impact on pain management technology.
Key updates include FDA clearances, clinical trial results, partnership announcements with medical institutions, and market penetration strategies. All content is sourced directly from official company communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to MLSS’s latest developments, enabling data-driven insights into its role in advancing precision anesthetic delivery worldwide.
Milestone Scientific (MLSS) anticipates a significant sales increase for Q4 2020, forecasting at least $1.7 million, marking a 40% sequential growth from Q3. The uptick is attributed to recovering dental operations post-pandemic and improved cash flow. The company has terminated exclusive distribution rights with Henry Schein, enhancing market penetration opportunities. The Wand® STA instrument's safety and efficiency are emphasized as it supports dental practices during COVID-19. Recent sales to a Chinese distributor of approximately $450,000 are expected but won’t be recorded until resold.
Milestone Scientific (MLSS) reported significant third-quarter developments. Dental sales rose over seven-fold compared to Q2 2020, aided by marketing promotions after COVID-19 disruptions. The company secured a purchasing agreement with Premier, enhancing its hospital reach. Despite this growth, Q3 revenues fell to approximately $1.2 million from $1.9 million year-over-year, with gross profit dropping to 67%. Operating loss increased to $(1.5) million due to reduced dental revenue. Cash reserves stood at over $14 million, supporting ongoing marketing and operational efforts.
Milestone Scientific Inc. (MLSS) will present at the Virtual Fall Investor Summit from November 16-18, 2020. Interim CEO Leonard Osser is scheduled to speak on November 18 at 9:30 a.m. ET. The presentation will be streamed live and available for replay. Investors can register for the conference or schedule one-on-one meetings through the Investor Summit Group. Milestone Scientific is known for its innovative injection technologies, focusing on precision and painlessness in medical and dental applications.
Milestone Scientific Inc. (NYSE: MLSS) announced a conference call for 8:30 AM ET on November 17, 2020, to discuss its third-quarter financial results for the period ending September 30, 2020. The call will address the company's corporate progress and developments. Interested parties can access the call via the company's website or by dialing specific numbers for U.S. and international callers. Milestone Scientific is known for its innovative computerized drug delivery instruments aimed at providing painless injections.
Milestone Scientific (MLSS) has published a video interview featuring Dr. Ayman A. Alian from Yale School of Medicine. The interview showcases the CompuFlo® Epidural System and CathCheck™, highlighting their benefits in improving epidural procedures. Dr. Alian emphasizes that these technologies enhance block efficiency, reduce complications, and improve patient satisfaction. CEO Arjan Haverhals expresses gratitude for Dr. Alian's support, reinforcing the technology's potential to become the standard in care.
Milestone Scientific (MLSS) announced a group purchasing agreement with Premier, effective November 1, 2020. This deal grants Premier’s network of approximately 4,100 hospitals and 200,000 providers preferred access to the CompuFlo® Epidural System and CathCheck™. The agreement aims to enhance healthcare delivery by offering special pricing and terms, reducing complication rates and hospital stay costs. This collaboration is expected to accelerate Milestone's commercialization efforts and improve health outcomes during the ongoing COVID-19 pandemic.
Milestone Scientific Inc. (NYSE American:MLSS) announced an investor webinar on September 14, 2020, at 4:00 p.m. ET, led by Interim CEO Leonard Osser. The session aims to discuss recent company developments and future milestones, followed by a live Q&A. Milestone is known for its innovative computerized drug delivery instruments, focusing on painless injections using its proprietary DPS Dynamic Pressure Sensing technology. Participants can register for the webinar online and pre-submit questions. The company emphasizes the forward-looking nature of its statements, which carry inherent risks and uncertainties.
Milestone Scientific (MLSS) anticipates a substantial increase in Q3 2020 dental revenues, projecting at least a four-fold rise compared to Q2 2020. The company's Wand® dental business is beginning to recover as dental offices reopen, aided by promotions to boost sales of disposables and instruments. Additionally, there is growth in active trials of the CompuFlo® Epidural System, with new partnerships and a strategy to shorten the sales cycle by lending instruments to hospitals. Overall, there is a robust sales pipeline and positive feedback from both domestic and international markets.
Milestone Scientific (MLSS) has announced the promotion of Jan Adriaan Haverhals to President, effective immediately. Haverhals, who joined the company in June 2020 as President and CEO of Wand Dental, brings over 30 years of experience in sales and marketing within the medical device sector. His leadership is expected to accelerate the commercialization of Milestone's CompuFlo® Epidural Instrument and CathCheck™ technologies in the U.S. and Europe. Leonard Osser, Interim CEO, expressed confidence in Haverhals' abilities to enhance sales and marketing efforts and foster collaborations with major health systems.
Milestone Scientific (NYSE American: MLSS) announced its participation in the LD 500 virtual investor conference from September 1-4, 2020. Interim CEO Len Osser will present on September 1 at 2:40 p.m. ET. The presentation will be available via a live webcast on the conference platform. One-on-one meetings can be requested online or via email. The LD 500 event will showcase key players in the small and micro-cap sector, featuring interviews and keynote speeches. For more details on Milestone Scientific's technology and services, visit their website.
FAQ
What is the current stock price of Milestone Scient (MLSS)?
What is the market cap of Milestone Scient (MLSS)?
